Andrea Juliana Gomes

Research interests

Publications

• Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial

  The Lancet · 2024 · 10.1016/s0140-6736(24)00317-9

• Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

  The Lancet Oncology · 2024 · https://doi.org/10.1016/s1470-2045(24)00100-1

• Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet · 2024 · 10.1016/s0140-6736(24)01808-7

• Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial

  Journal of Clinical Oncology · 2024 · 10.1200/jco-24-01798

• Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial

  Journal of Clinical Oncology · 2024 · 10.1200/jco-24-01798

• Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer

  Annals of Oncology · 2023 · 10.1016/j.annonc.2023.02.009

• Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

  Journal of Clinical Oncology · 2023 · https://doi.org/10.1200/jco.22.01649

• Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

  Journal of Clinical Oncology · 2023 · https://doi.org/10.1200/jco.22.01649

• Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial

  Annals of Oncology · 2023 · 10.1016/j.annonc.2023.06.009

• Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations.

  Journal of Clinical Oncology · 2022 · 10.1200/jco.2022.40.6_suppl.012

• Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

  Journal of Clinical Oncology · 2021 · 10.1200/jco.20.03488

• Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study

  The Lancet Oncology · 2019 · 10.1016/s1470-2045(19)30620-5

• Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1903307

Current projects

No projects listed.